Aduro Biotech to Host a Program Update Call
December 11 2017 - 4:01PM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, today announced that the
company will host a conference call to provide an update on its
programs tomorrow, Tuesday, December 12, 2017 at 8:30 am Eastern
Time. To participate in the conference call, please dial
(844) 309-0604 (domestic) or (574) 990-9932 (international) and
refer to conference ID 2455008.
Live audio of the conference call will be simultaneously webcast
and available to members of the news media, investors and the
general public under the investor section of the Aduro website at
investors.aduro.com.
The webcast will be archived and available for replay for one
month following the event.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, gastric, ovarian, lung and prostate cancers.
Additionally, a personalized form of LADD, or pLADD, is in Phase 1
development utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the STING receptor in immune
cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in development, including BION-1301, an anti-APRIL antibody.
Aduro is collaborating with leading global pharmaceutical companies
to expand its products and technology platforms. For more
information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, our
plans, the timing and availability of results of our clinical
trials and those of our collaborators, the timing and receipt of
milestone payments, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify
these statements by forward-looking words such as “may,” “believe,”
“will,” “continue,” “anticipate,” “intend,” “could,” “project,”
“expect,” “targeted” or the negative or plural of these words or
similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our history of net operating losses and uncertainty regarding our
ability to achieve profitability, our ability to develop and
commercialize our product candidates, our ability to use and expand
our technology platforms to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, our reliance on third parties, and
our ability to obtain and adequately protect intellectual property
rights for our product candidates. We discuss many of these risks
in greater detail under the heading “Risk Factors” contained in our
quarterly report on Form 10-Q for the quarter ended September 30,
2017, which is on file with the Securities and Exchange Commission.
Any forward-looking statements that we make in this press release
speak only as of the date of this press release.
Contact:
Sylvia
Wheeler
SVP, Corporate
Affairs
510 809
9264
Media Contact:Aljanae Reynolds 510 809 2452press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2024 to May 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From May 2023 to May 2024